203 related articles for article (PubMed ID: 14720633)
1. Incentives and pharmaceutical reimbursement reforms in Spain.
Puig-Junoy J
Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical expenditure in Spain: cost and control.
Lopez Bastida J; Mossialos E
Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
[TBL] [Abstract][Full Text] [Related]
3. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
Schwermann T; Greiner W; v d Schulenburg JM
Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
[TBL] [Abstract][Full Text] [Related]
4. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
5. Reference pricing for drugs: is it compatible with U.S. health care?
Kanavos P; Reinhardt U
Health Aff (Millwood); 2003; 22(3):16-30. PubMed ID: 12757268
[TBL] [Abstract][Full Text] [Related]
6. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
7. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
Murry L; Gerleman B; Urick B; Urmie J
J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
[TBL] [Abstract][Full Text] [Related]
8. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
Antoñanzas F
Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
[TBL] [Abstract][Full Text] [Related]
9. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
10. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
[TBL] [Abstract][Full Text] [Related]
11. Economic aspects of the new Spanish laws on pharmaceutical preparations.
Antoñanzas F; Oliva J; Pinillos M; Juàrez C
Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical reform in South Korea and the lessons it provides.
Kim HJ; Ruger JP
Health Aff (Millwood); 2008; 27(4):w260-9. PubMed ID: 18508813
[TBL] [Abstract][Full Text] [Related]
13. Pricing and reimbursement of pharmaceuticals in Sweden.
Jönsson B
Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
[TBL] [Abstract][Full Text] [Related]
14. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
15. An Rx for reform: a Medicare prescription drug benefit.
Rak J
Health Matrix Clevel; 2002; 12(2):449-505. PubMed ID: 12430363
[No Abstract] [Full Text] [Related]
16. Medicaid prescription drug coverage: state efforts to control costs.
Gencarelli DM
NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
[TBL] [Abstract][Full Text] [Related]
17. Public drug expenditure in the Republic of Ireland.
Barry M; Usher C; Tilson L
Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
[TBL] [Abstract][Full Text] [Related]
18. Estimating a reasonable reimbursement for community pharmacies in third-party programs.
Carroll NV
Manag Care Interface; 1999 Feb; 12(2):73-6, 79-80. PubMed ID: 10346189
[TBL] [Abstract][Full Text] [Related]
19. [Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients].
Gouya G; Reichardt B; Bidner A; Weissenfels R; Wolzt M
Wien Klin Wochenschr; 2008; 120(3-4):89-95. PubMed ID: 18322770
[TBL] [Abstract][Full Text] [Related]
20. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.
Antoñanzas F; Gómez P
Pharmacoeconomics; 2010; 28(11):977-80. PubMed ID: 20936881
[No Abstract] [Full Text] [Related]
[Next] [New Search]
